dsorchestra90
Long

Gilead- Staying long

NASDAQ:GILD   GILEAD SCIENCES INC
Technicals look fairly good, but perhaps slightly over-brought in the near term.

GILD's monster quarter helped the shares jolt upward and break through the medium-term downtrend that hit the stock after fears over margins for Harvoni & Sovaldi.
- Q1 Earnings: Decimated Revs & EPS            
-Q1 Earnings:Margins not hit as badly as expected
-HIV & Nash mitigate one trick pony risk
-Shrewd management that has avoided expensive M&A, and has historically made excellent acquisition decisions (e.g. Pharmasset in 2011) If the recent moves into oncology by acquiring EpiTherapeutics prove to be anywhere near as -fruitful as Hep-C, shareholders will profit handsomely.
-Although the recent foray into Hep-B was unsuccessful, this is an area to look out for (huge growth opportunity)
Ideas Scripts Chart
United States
United Kingdom
India
España
Italia
Brasil
Россия
Türkiye
日本
한국
Home Stock Screener Economic Calendar How It Works Chart Features House Rules Moderators For the WEB Widgets Stock Charting Library Priority Support Feature Request Blog & News FAQ Help & Wiki Twitter
Private Messages Chat Ideas Published Followers Following Priority Support Public Profile Profile Settings Billing Sign Out